Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
Devlin-MacGregor, a pharmaceutical company that is releasing a new drug called Provasic. Kimble had previously analyzed the drug's test samples and discovered it caused liver damage, which should have prevented Food and Drug Administration approval. Kimble and a colleague deduce that Dr. Nichols, who led the drug's development and will profit from sales, arranged a cover-up by falsifying the findings to get Provasic approved.......we know the rest..............
interesting comment below..
Rajraj b
9 Jan '22 - 12:46 -
When I was reviewing papers for my Msc dissertation (many years ago), the first thing you would IGNORE is the conclusion and results of these papers. You would first look at the methodology. If this was sound then I’d read the paper. In this case, using frozen pig mucus as opposed to live human viral samples is a failing in the methodology. I’m not sure, but does any other assessing system use frozen pig mucus or is that a peculiarity of the U.K.? And does using one type of outcome agent misleadingly favour certain LFT’s over others? Questions need to asked. Is it the LFT that is failing or is it the assessing test that’s the problem?
>>>>>>>>>>
“It’s just baffling that you would put so much effort into UK manufacturing and then turn round and say we don’t want to purchase.”
She added: “It seemed to get caught up with the Good Law Project.”
Placeholder image for youtube video: qTZzJHGhED4
Another industry insider said the episode had resulted in a “complete lack of trust” between manufacturers and the Department of Health and Social Care.
“A lot of these firms wanted to help out of a spirit of public service, but after this they won’t go near the government again without a lot of money up front.
“There’s a strong feeling that the government backed out because of fear of judicial reviews and the Good Law Project.”
The Good Law Project launched a high profile judicial review against the government for its £75 million contract for lateral flow tests with Abingdon Health.
The deal was abandoned last January after the government said Abingdon’s test had not passed scrutiny by the Medicines and Healthcare products Regulatory Agency.
The British Government could be facing calls to explain the 'baffling' decision to rely on securing Chinese-made testing kitsBy Henry Bodkin, senior reporter 31 December 2021 • 9:38pmPlans to manufacture lateral flow tests in the UK were shelved amid fears of legal challenges over the Government’s alleged “chumocracy”, it has been claimed.In the early months of 2021, ministers called a halt to months of work with British companies that had been intended to establish an onshore manufacturing capability for the rapid Covid tests.The result has left the UK relying on securing Chinese-made kits, with the devices currently unavailable in many parts of the country.The shortage threatens to prevent people returning to work next week, and to hamper efforts to clamp down on the spread of omicron.On Friday, figures in the diagnostics industry pointed to a slew of legal actions against Boris Johnson’s Government by the Good Law Project to explain the “baffling” decision not to build manufacturing capability in the UK.The campaign organisation, which is led by Jolyon Maugham QC, a Remain-supporting barrister, uses judicial review actions in the High Court to challenge government policy and actions it disagrees with.The group has launched cases opposing government policy on Brexit and, more recently, against procurement decisions in the pandemic response.The scrutiny has contributed to a criticism of a “chumocracy” against senior ministers, including Matt Han****, who came under fire after a contract was awarded to a business owner who used to run a pub close to the former health secretary’s home.Mr Han**** has strenuously denied any personal wrongdoing, while ministers more broadly have defended bypassing some civil service procurement red tape in the early stages of the pandemic due to the urgency of the crisis.The Good Law Project is led by Jolyon Maugham QCThe Good Law Project is led by Jolyon Maugham QC Credit: Andrew Milligan/PA Wire/Andrew Milligan/PA WireDoris-Ann Williams, the chief executive of the British In Vitro Diagnostics Association, said that Lord Bethel, the junior health minister, had encouraged a consortium of companies to push ahead with research and development into lateral flow tests from autumn 2020, but that the drive had been scrapped in early in 2021, with no adequate reason given.“They threw a lot of money at it and encouraged the companies to ramp up their manufacturing capability, but when it got to the crucial point the government said it was never their intention to purchase,” she said.“For some reason they went to the Chinese.“It’s just baffling that you would put so much effort into UK manufacturing and then turn round and say we don’t want to purchase.”She added: “It seemed to get caught up with the Good Law Project.”Placeholder image f
FlowFlex U.K. has all the approvals to sell commercially in the U.K. - yet operates from someones cottage . Needs investigating ?@AngelaRayner
? #odx #abdx #avct ?@Omega_ODX
Your name
Your email
Subject
Your message (optional)
Business Address
Ratcliffe Cottage
2 Toothill Road
Loughborough
Leicestershire
LE11 1PW
Contact Information
Email: info@flowflexrapidtest.com
Customer Service Opening Times:
Monday to Friday: 9:00am to 6:00pm
Saturday, Sunday and Bank Holidays: 10:00am to 4:00pm
Telephone: 0208 087 2981
FlowFlex Rapid Test is a trading name of Argyle Rose Limited, a company registered in England & Wales under Co. Reg. No. 11018049.
Argyle Rose Limited has its registered office address at Ratcliffe Cottage, 2 Toothill Road, Loughborough, Leicestershire LE11 1PW. Argyle Rose Limited is VAT registered and its VAT Reg No is: GB 353 1579 95.
A list of its directors is available for inspection at its registered office.
? ?
How they sell UK without CTDA ?
Marcus Blackburn
@mdbburn
·
9m
They were granted Emergency Use Authorisation after supplying brown envelopes
Richard Armstrong
@VisionaryProp
,
@AngelaRayner
and
@Omega_ODX
I've just had a look at that Dom and it's worth a proper look. Net worth of Company just over 5k in the last accounts. 9 other companies registered at the same address. 6 with proposals to strike off. Just what you'd expect....., NOT ? #Avct.
.
https://amp.elmundo.es/como/2021/12/21/61c09f24fc6c831b098b45e9.html
Neale Hanvey MP ?????????????????
@JNHanvey
·
1h
Almost everything
@BorisJohnson
’s government have said about domestic diagnostics has been either wrong, misleading or utterly dishonest and untrue.
All the while they wave through underperforming generic imports and hand £billions to profiteering middlemen.
It has to stop.
https://twitter.com/search?q=%23Avct&f=live
a breaking unavoidable s-storm....for those who should be held to account...
BIVDA Press Releases
07Jan
BIVDA Press Release - BIVDA seeks to clarify incorrect claims made by media outlets and the PM regarding the UK's pre-pandemic lateral flow device manufacturing capability
Return
Recent statements relating to the lack of ability for the UK to manufacture lateral flow test devices have included information which has been misleading and distorted the facts. As the trade association representing nearly 200 organisations, which includes both British and global diagnostic companies, BIVDA would like to clarify these facts.
The UK Diagnostics Industry has suffered decades of underinvestment by public sector innovation funders, and poor adoption of its new products by the NHS due to fragmented procurement and treatment strategies. The UK industry actually pioneered the global development and manufacture of lateral flow technologies. The many UK diagnostics manufacturers of advanced lateral flow tests have been driven to focus on export, both to other first world markets and for use in diagnosing disease in the developing world, where access to laboratory testing is difficult.
The unprecedented and welcome investment provided by the Government for increasing manufacturing capacity (and the raw material supplies required for this) during the pandemic should have been an opportunity to address a number of issues. Not only would this investment helped tackle Covid-19 head on but it would have ensured that the IVD industry, which responded immediately to the government’s call to action, was able to have a sustained future. Prepared for any future pandemic, allowing the British public to benefit from UK-based technologies and our Treasury to benefit from the jobs that would have been created in the diagnostics sector.
To be clear, procurement decisions were taken to source lateral flow tests from inside and outside of the UK and only to use the enhanced manufacturing capacity for UK tests that were bought by NHS Test & Trace. This once in a generation opportunity has not been fully realised and has instead damaged parts of the UK-based industry to a point of crisis and soured the relationships between an industry who instinctively stood up to be counted, and their government.
ENDS
.>>>>>>
Please use the sharing tools found via the share button at the top or side of articles. Copying articles to share with others is a breach of FT.com T&Cs and Copyright Policy. Email licensing@ft.com to buy additional rights. Subscribers may share up to 10 or 20 articles per month using the gift article service. More information can be found at https://www.ft.com/tour.
https://www.ft.com/content/46f2e45a-adc2-4337-bdac-648f315f9a78
The vagueness of this announcement is staggering. Once again the government is guilty of issuing confusing advice which creates worry and distress for potentially affected workers,” she said. “It rapidly needs to be made entirely clear which workers will or won’t be labelled as critical.”
Meanwhile, Johnson announced on Wednesday that from 4am on Friday travellers coming into England will no longer have to take a pre-departure test. He added that travellers will be able to take a lateral flow test instead of a PCR on the second day after their arrival, removing the requirement to self isolate until they receive a negative PCR result.
Heathrow airport welcomed the news, saying it represented a “much-needed boost to passengers”.
Coronavirus testing rules in England will also be eased next week, as concerns rise over the country’s testing capacity and the continued impact of staff shortages on critical public services.
Under changes announced by the UK Health Security Agency on Wednesday, starting from January 11 individuals who are asymptomatic but test positive on a lateral flow device will be expected to report their results and self-isolate but will no longer be advised to take a follow-up PCR test.
A health official told the Financial Times that the move would free up “extra testing capacity” as the PCR testing system comes under pressure from soaring infection rates.
https://www.ft.com/content/46f2e45a-adc2-4337-bdac-648f315f9a78
https://www.ft.com/content/46f2e45a-adc2-4337-bdac-648f315f9a78
Business groups have stepped up calls for the UK government to get a “grip” on shortages of rapid Covid-19 tests, warning that they were vital to keeping the economy on track.
Roger Barker, director of policy at the Institute of Directors, said the government should enable companies to allow employees to take a daily test. He added: “Clearly at the moment there are problems with the supply of lateral flow tests that makes this unfeasible. Therefore the government needs to urgently address the current supply shortages.”
Matthew Fell, head of policy at the CBI, said: “It is now vital that wider testing supply challenges are gripped.”
The government launched a programme last April to give free tests to companies for their employees, but it was shelved just three months later. Some business groups have asked for the scheme to be revived. “We want free lateral tests to be available to employers so they have that option available if they want to introduce it themselves,” said Make UK, the manufacturers’ association.
Craig Beaumont, chief of external affairs at the Federation of Small Businesses, urged the government to get a “grip” to sort out the supply of lateral flow tests. “The online LFT website has now been down for well over a week, without any deadline or even a vague aim for it to come back,” he said. “With pharmacies running dry and the workplace testing programme shut down, the whole testing infrastructure is disintegrating. This needs some grip to sort out.”
Boris Johnson, prime minister, on Tuesday announced that about 100,000 key workers in several industries — “from food processing to transport to Border Force” — would from have to take daily Covid-19 tests, delivered by the government. Officials said relevant employers would be contacted in the coming days, with details of the scheme still being finalised.
Businesses operating within sectors such as transport have been asked to provide relevant government departments with figures on how many staff are needed to keep critical services running, which will help to determine the allocation of tests, according to Whitehall officials with knowledge of discussions.
Unions called for greater clarity surrounding the practicalities of the scheme, which is due to come into effect next week. Unite general secretary Sharon Graham said there were far more than 100,000 workers employed in the three sectors highlighted by Johnson.
“The vagueness of this announcement is staggering. Once again the gover............>>>>
#AVCT
USA lateral flow Tests may not make the grade
They need a better test... perhaps we can help Thinking faceFlag of United Kingdom
dailymail.co.uk
Lateral flows may FAIL to spot Omicron when people are most infectious
US researchers found it took an average of three days longer for people to test positive on a lateral flow test after their infection had already been confirmed on a PCR test.
https://www.dailymail.co.uk/news/article-10378509/Lateral-flow-tests-FAIL-spot-Omicron-people-infectious-study-warns.html
https://www.lse.co.uk/rns/AVCT/affidx174-lateral-flow-test-detects-omicron-variant-2bo9p7ih95fsnem.html
AffiDx® lateral flow test detects Omicron variant
Wed, 15th Dec 2021 07:00
https://www.fdanews.com/articles/206037-avactas-affidx-covid-19-antigen-self-test-receives-ce-mark
Avacta’s AffiDX COVID-19 Antigen Self-Test Receives CE Mark
January 5, 2022
Cambridge, UK-based Avacta Group has received a CE mark certification for its AffiDX SARS-CoV-2 rapid antigen self-test.
The company partnered with Medusa Healthcare to secure regulatory approval for the test, which Medusa will market under the brand name MeduFlow.
The AffiDX test, which delivers a result in 20 minutes, was clinically validated at the Carlos III hospital in Madrid, Spain, where it was shown to have a sensitivity across a broad range of viral loads of 98 percent and a specificity of 99 percent.
The #COVID19 pandemic has certainly supercharged #AVCT's growth prospects.
Regardless of whether pre CISION works in man, I think the Affimer Diagnostics platform will now go on to achieve a valuation of several $ billion (at least!) in the coming year
https://twitter.com/MylesMcNulty?ref_src=twsrc%5Egoogle%7Ctwcamp%5Eserp%7Ctwgr%5Eauthor
Even if the jabs are less effective at stopping omicron, they appear to have helped turn it into a relatively benign virus that no longer warrants the unhinged response we still see both here and around the world. In China, the ancient capital of Xi’an with a population of 13 million has been in a lockdown of such severity after just a few cases that people have not been able to get food. They may die of malnutrition but at least they haven’t got Covid.
Beijing’s policy of mass testing, quarantines and sudden lockdowns has been followed in Europe and elsewhere and yet the virus, albeit in a milder form, is more rampant than ever. The really frightening thought is that when we come to mark the third anniversary of the outbreak, we may still be trapped in this baleful cycle. If "living with Covid" as an endemic disease is to mean anything, it must involve targeting vaccines annually only at the most vulnerable, not the entire population, and the end of mass testing.
The so-called Operation Moonshot project was supposed to create a home-grown production industry yet just one UK company has so far passed strict regulations. Firms like Avacta Life Sciences based in Yorkshire say they have a world-beating product which is certified for use in Europe but not in the UK. Why not? Other manufacturers tell a similar story. Given the recent shortage of test kits, it beggars belief that regulatory hold-ups are making matters worse while also leaving us dependent on companies based in China.
In view of the deepening diplomatic tensions between the West and Beijing, is this sensible? Neale Hanvey, MP for Kirkaldy and Cowdenbeath, who has been banging on about this for some time, has an adjournment debate in the Commons tonight to draw further attention to the issue. As he said in PMQs before Christmas: "Can the Government please explain why they have pulled the plug on the UK diagnostics industry when additional capacity is so obviously required? It is beyond illogical."
The Government says the companies do not pass rigorous quality controls but the manufacturers say theirs are more accurate than the Chinese tests; so what is going on? Someone in the Government needs to get a grip of this for as long as they insist on mass testing as a requirement for us all to live a normal life, from attending school to going into work.
And there, of course, is the rub. The big question that needs to be asked now is: should we test at all? The evident mildness of omicron compared to previous variants suggests that we need to treat Covid the way we deal with all other respiratory illnesses, with a mix of treatments and vaccines. We do not test and isolate for a cold or flu, though the latter usually requires days in bed to recover. One reason we have many more positive cases than most places in Europe is because we test more and we do that largely because the kits are handed out for free whereas elsewhere they have to be paid for.
The mass testing of perfectly healthy people would have been considered insane just a few years ago, yet is now a national orthodoxy. Lining up children before they go to school to have a swab stuck up their noses to check for a disease that they probably have not got – and which will affect them very mildly if they do have it – is not only bonkers, it is inhuman, as is requiring they wear masks in the classroom.
Mass testing may have made sense at the start of the pandemic when, in the absence of a vaccination, it seemed to offer the only way through other than letting the disease take its natural course with consequences that we cannot know. Boris Johnson hoped that Operation Moonshot would give people freedom to mingle, and yet here we are, still told to work from home if we can.
Even if the jabs are less effective at stopping omicron, they appear to have helped turn it into a relatively benign virus that no longer warrants the unhinged response we still see both here and around the world.
Comment
Chinese-style mass testing must end if we’re ever to learn to live with Covid
It’s galling that the country where the virus emerged is making money by selling the rest of the world test kits
Philip Johnston
4 January 2022 • 9:30pm
Philip Johnston
On January 5 two years ago, the World Health Organisation issued a seemingly innocuous bulletin under the headline "Pneumonia of unknown cause – China". It was the first inkling of a novel coronavirus outbreak which by then had infected around 50 people in the city of Wuhan.
The WHO’s assessment was reassuring, even complacent given what we know now but didn’t then. "Based on the preliminary information from the Chinese investigation team, no evidence of significant human-to-human transmission and no health care worker infections have been reported," it said. Immediately, the finger of suspicion was pointed at the fish and live animal markets in Wuhan, helpfully (from Beijing’s point of view) drawing attention away from another possible source, a laboratory where experiments were conducted on precisely these pathogens.
One of the many great mysteries of the subsequent response to the pandemic has been the extraordinary efforts to which some in the West have gone to exculpate China from this disaster. Here is a totalitarian dictatorship which even to this day refuses to pass over all the information needed to understand the trajectory of the pandemic, yet which is somehow seen as a victim. For some time even to suggest that the virus might have escaped from a lab (and no-one was saying it was deliberate) was to be denounced, presumably because it was a view pushed by Donald Trump. Facebook even censored any reference to the possibility of a lab leak as fake news.
Now, many scientists at least accept that this possible cause of the pandemic is "credible" if not proven. It probably never will be. The consequences of it being true, of course, are profound since it would show an appalling laxity of bio-security at a laboratory which would have been responsible for 3.5 million fatalities and the deaths of millions more from unrelated medical conditions that have gone untreated. The damage to livelihoods, education and mental health is incalculable.
It is galling, then, to pick up a lateral flow test kit and see the words Made in China emblazoned on it, which if they were being given to the world for nothing would at least be some contribution to the damage caused but for which we have paid a great deal of money. Moreover, the Government has spent billions on lateral flow test kits manufactured in China while British firms have struggled to obtain approval for their own.
The so-called Operation Moonshot project was supposed to create a home-grown production industry yet just one UK company has so far passed strict regulations. Firms like Avacta Life Sciences based in Yorkshire say they have a world-beating product which is certified for use in Europe but not in the UK. Why n
Re your Sunday Times article...you might find the enclosed informative... Mon, Jan 3, 2022 1:03 pm
To emily.dugan@sundaytimes.co.uk emily.dugan@sundaytimes.co.uk
fyi...
Stop Using Innova Medical Group SARS-CoV-2 Antigen Rapid
https://www.fda.gov › safety-communications › stop-us...
10 Jun 2021 — On April 23, 2021, Innova Medical Group recalled their Innova Medical Group SARS-CoV-2 Antigen Rapid Qualitative Test. The FDA has identified ...
How Innova got billions selling COVID tests to UK government
https://www.latimes.com › business › story › innova-pa...
28 Jul 2021 — Innova Medical Group in Pasadena secured contracts worth at least $2.7 billion selling Chinese-made antigen tests to the U.K. government ...
U.K. doubles down on Innova's rapid COVID-19 test, after FDA ...
https://www.fiercebiotech.com › medtech › u-k-doubles...
18 Jun 2021 — A week after the FDA urged anyone who had Innova Medical Group's COVID-19 antigen test to stop using it and toss it in the trash, ...
TallPaulNY...send all this to the lady at the Times please..
email address pls